Search research articles
Contact Us
Filters
Showing results (11-20 of 84) with videos related to
Page
of 9
Sort By:
Israel Journal of Medical Sciences
|
November 1, 1994
Use of the APACHE II severity score in an Israeli GICU
M Hersch, D Elstein, A Zimran
Acta Neurologica Scandinavica
|
March 23, 2007
Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?
A Halperin, D Elstein, A Zimran
Clinical Genetics
|
October 27, 1998
Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease
D Elstein, A Abrahamov, A Zimran
Bailliere'S Clinical Haematology
|
March 14, 1998
Skeletal involvement in Gaucher's disease
D Elstein, M Itzchaki, H J Mankin
QJM : Monthly Journal of the Association of Physicians
|
January 2, 2003
Decreased salivary output in patients with Gaucher disease
B Dayan, D Elstein, A Zimran, et al.
Blood Cells, Molecules & Diseases
|
December 17, 2002
Chitotriosidase deficiency in survivors of Candida sepsis
M Masoud, B Rudensky, D Elstein, et al.
The Israel Medical Association Journal : IMAJ
|
September 29, 2001
How B12 deficiency can impact on the individual and how society can impact on B12 deficiency
Y Gielchinsky, D Elstein, A Abrahamov, et al.
Blood Cells, Molecules & Diseases
|
October 29, 1998
Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease
D Elstein, A Abrahamov, M Itzchaki, et al.
American Journal of Human Genetics
|
October 20, 2001
Ethical guidelines for enzyme therapy in neuronopathic Gaucher disease
D Elstein, A Steinberg, A Abrahamov, et al.
British Journal of Haematology
|
September 6, 2000
Withdrawal of enzyme replacement therapy in Gaucher's disease
D Elstein, A Abrahamov, I Hadas-Halpern, et al.
Page
of 9
Search research articles
Search
Showing results (11-20 of 84) with videos related to
Sort By:
Page
of 9
Israel Journal of Medical Sciences
|
November 1, 1994
Use of the APACHE II severity score in an Israeli GICU
M Hersch, D Elstein, A Zimran
Acta Neurologica Scandinavica
|
March 23, 2007
Are symptoms of peripheral neuropathy more prevalent in patients with Gaucher disease?
A Halperin, D Elstein, A Zimran
Clinical Genetics
|
October 27, 1998
Ethical considerations for enzyme replacement therapy in neuronopathic Gaucher disease
D Elstein, A Abrahamov, A Zimran
Bailliere'S Clinical Haematology
|
March 14, 1998
Skeletal involvement in Gaucher's disease
D Elstein, M Itzchaki, H J Mankin
QJM : Monthly Journal of the Association of Physicians
|
January 2, 2003
Decreased salivary output in patients with Gaucher disease
B Dayan, D Elstein, A Zimran, et al.
Blood Cells, Molecules & Diseases
|
December 17, 2002
Chitotriosidase deficiency in survivors of Candida sepsis
M Masoud, B Rudensky, D Elstein, et al.
The Israel Medical Association Journal : IMAJ
|
September 29, 2001
How B12 deficiency can impact on the individual and how society can impact on B12 deficiency
Y Gielchinsky, D Elstein, A Abrahamov, et al.
Blood Cells, Molecules & Diseases
|
October 29, 1998
Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease
D Elstein, A Abrahamov, M Itzchaki, et al.
American Journal of Human Genetics
|
October 20, 2001
Ethical guidelines for enzyme therapy in neuronopathic Gaucher disease
D Elstein, A Steinberg, A Abrahamov, et al.
British Journal of Haematology
|
September 6, 2000
Withdrawal of enzyme replacement therapy in Gaucher's disease
D Elstein, A Abrahamov, I Hadas-Halpern, et al.
Page
of 9